Literature DB >> 14573882

Severe chronic obstructive pulmonary disease.

Ken Y Yoneda1, Richart W Harper, Samuel Louie.   

Abstract

Chronic obstructive pulmonary disease (COPD) exacts a heavy toll on society, yet its prevention, diagnosis and treatment receives inadequate attention from both the medical community and from society at large. Guidelines released in 2001 from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) are aimed at redressing this inequity. In this review, we integrate information from the GOLD guidelines with recent updates on the prevention, treatment and management as related specifically to the most severe form of this disease. In order to help distinguish COPD from other disorders that may mimic or confound its treatment, we place particular emphasis on the definition, underlying pathophysiology and diagnosis of COPD. In addition, we discuss future directions in pharmacotherapy.

Entities:  

Mesh:

Year:  2003        PMID: 14573882     DOI: 10.1385/CRIAI:25:2:151

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  91 in total

1.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

2.  Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.

Authors:  S G Adams; J Melo; M Luther; A Anzueto
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.

Authors:  Robert Wise; John Connett; Gail Weinmann; Paul Scanlon; Melissa Skeans
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

5.  Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial.

Authors:  T Troosters; R Gosselink; M Decramer
Journal:  Am J Med       Date:  2000-08-15       Impact factor: 4.965

6.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.

Authors:  R Dahl; L A Greefhorst; D Nowak; V Nonikov; A M Byrne; M H Thomson; D Till; G Della Cioppa
Journal:  Am J Respir Crit Care Med       Date:  2001-09-01       Impact factor: 21.405

7.  Gain and subsequent loss of lung function after lung volume reduction surgery in cases of severe emphysema with different morphologic patterns.

Authors:  Konrad E Bloch; Carmina L Georgescu; Erich W Russi; Walter Weder
Journal:  J Thorac Cardiovasc Surg       Date:  2002-05       Impact factor: 5.209

Review 8.  Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review.

Authors:  L van Ede; C J Yzermans; H J Brouwer
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

9.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.

Authors:  N R Anthonisen; J E Connett; J P Kiley; M D Altose; W C Bailey; A S Buist; W A Conway; P L Enright; R E Kanner; P O'Hara
Journal:  JAMA       Date:  1994-11-16       Impact factor: 56.272

10.  Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.